Needle lost in the haystack: multiple reaction monitoring fails to detect *Treponema pallidum* candidate protein biomarkers in plasma and urine samples from individuals with syphilis [version 2; peer review: 2 approved]

Geert A. Van Raemdonck¹,²*, Kara K. Osbak¹*, Xaveer Van Ostade²*, Chris R. Kenyon¹,³*

¹HIV/STI Unit, Institute of Tropical Medicine, Antwerp, 2000, Belgium
²Laboratory for Protein Science, Proteomics and Epigenetic Signalling (PPES) and Centre for Proteomics (CFP), University of Antwerp, Wilrijk, 2610, Belgium
³Division of Infectious Diseases and HIV Medicine, University of Cape Town, Cape Town, 7925, South Africa

* Equal contributors

Abstract

**Background:** Current syphilis diagnostic strategies are lacking a sensitive manner of directly detecting *Treponema pallidum* antigens. A diagnostic test that could directly detect *T. pallidum* antigens in individuals with syphilis would be of considerable clinical utility, especially for the diagnosis of reinfections and for post-treatment serological follow-up.

**Methods:** In this study, 11 candidate *T. pallidum* biomarker proteins were chosen according to their physiochemical characteristics, *T. pallidum* specificity and predicted abundance. Thirty isotopically labelled proteotypic surrogate peptides (hPTPs) were synthesized and incorporated into a scheduled multiple reaction monitoring assay. Protein extracts from undepleted/unenriched plasma (N = 18) and urine (N = 4) samples from 18 individuals with syphilis in various clinical stages were trypically digested, spiked with the hPTP mixture and analysed with a triple quadrupole mass spectrometer.

**Results:** No endogenous PTPs corresponding to the eleven candidate biomarkers were detected in any samples analysed. To estimate the Limit of Detection (LOD) of a comparably sensitive mass spectrometer (LTQ-Orbitrap), two dilution series of rabbit cultured purified *T. pallidum* were prepared in PBS. Polyclonal anti-*T. pallidum* antibodies coupled to magnetic Dynabeads were used to enrich one sample series; no LOD improvement was found compared to the unenriched series. The estimated LOD of MS instruments is 300 *T. pallidum/ml* in PBS.

Open Peer Review

Invited Reviewers

1. Mohd M. Khan, University of Maryland, Baltimore, USA
2. Timothy Palzkill, Baylor College of Medicine, Houston, USA

Any reports and responses or comments on the article can be found at the end of the article.
Conclusions: Biomarker protein detection likely failed due to the low (femtomoles/liter) predicted concentration of *T. pallidum* proteins. Alternative sample preparation strategies may improve the detectability of *T. pallidum* proteins in biofluids.

Keywords: MRM, Multiple Reaction Monitoring, targeted proteomics, Treponema pallidum, syphilis, biomarker discovery, antigen test, plasma
**List of abbreviations**

hPTPs Isotopically labelled proteotypic surrogate peptides  
LOD Limit of detection  
MSM Men who have sex with men  
PCR Polymerase chain reaction  
TPPA Treponema pallidum Particle Agglutination test  
RPR Rapid plasma reagin test  
COG Clusters of Orthologous Groups  
FA Formic acid  
PBS Phosphate buffered saline  
NSAF Normalized spectral abundance factor  
IQR Interquartile range  

SISCAPA Stable Isotope Standards and Capture by Anti-Peptide Antibodies

**Introduction**

*Treponema pallidum* ssp. *pallidum* (*T. pallidum*), a culturable microaerophilic spirochete, is responsible for more than 8 million new cases of syphilis per year. There has been a resurgence of syphilis in a number of world regions over the last two decades. In Europe and North America, this increase has been most marked in men who have sex with men (MSM). A striking feature of these outbreaks has been the increasing proportion of cases that are occurring in patients with a previous diagnosis of syphilis. Patients with reinfections are more likely to present with asymptomatic or less symptomatic disease, hence the diagnosis of reinfection is wholly dependent on subtle changes in serological tests. Two types of serological tests are used to diagnose syphilis: treponemal tests detect antibodies to *T. pallidum* and non-treponemal tests, such as the Rapid plasma reagin (RPR) test, detect agglutination secondary to the presence of anti-lipoidal antibodies reactive to material released from damaged host cells and possibly cardiolipin released from *T. pallidum*. Treponemal tests remain positive for life and are therefore of no use in the diagnosis of reinfection. Non-treponemal tests are used for syphilis post-treatment follow-up and diagnosis of reinfection. A wide range of factors can result in increases in test titers, causing syphilis to be over-diagnosed and unnecessarily treated. Direct *T. pallidum* detection techniques, including various nucleic acid amplification tests, have been developed, but apart from testing of primary ulcer specimens the sensitivity of these techniques is low. Even in the setting of secondary syphilis, when there is a high *T. pallidum* load in the blood, the sensitivity of polymerase chain reaction (PCR) tests reaches only 52% on serum specimens.

The *T. pallidum* genome, through evolutionary reduction, is one of the smallest of the human bacterial pathogens, with a predicted 1044 open reading frames. Approximately half of the predicted proteins have been detected through MS techniques, including the semi-quantification of *T. pallidum* proteins using spectral counting. A *T. pallidum* transcriptome study demonstrated that almost all genes were expressed during peak rabbit experimental infection. This maximum utilization of the genome, well characterized proteome, and swift invasion of the organism into the bloodstream (within 24 hours after infection) make this pathogen an ideal candidate for antigen diagnostic assay development. A variety of antigen tests against other pathogens have been designed for clinical samples such as blood, cerebrospinal fluid, faeces and urine; and these have proven their utility in the diagnosis and assessment of therapeutic response in a number of infections, including *Helicobacter pylori*, *Cryptococcus neoformans*, *Cryptosporidium ssp.* and *Entamoeba histolytica*, *Ebola virus* and *Mycobacteria tuberculosis*. If a highly sensitive and specific test could be developed that is able to confirm the presence or absence of *T. pallidum* in the body then this would be of considerable utility in the diagnosis of syphilis reinfections and in assessing therapeutic response. It could also be useful for the diagnosis of neuro- and congenital syphilis – two diagnoses where contemporary tests are suboptimal.

During the last decade, advanced MS-based proteomics platforms have emerged as mainstay bioanalytical tools for a broad range of clinical applications, including targeted protein identification and bacteria identification and typing. Particularly the AQUA workflow, with its use of stable isotopically labelled standard proteotypic peptides (henceforth referred to as ‘heavy’ PTPs or hPTPs) and selected/multiple reaction monitoring-mass spectrometry (SRM/MRM MS), has emerged as a powerful technique for the fast determination of multiple protein concentrations in highly complex sample matrices such as urine (reviewed by Mermelekas et al.) and plasma (reviewed by Pernemalm and Lehtiö). Precise quantitation of proteins is possible by using hPTPs as internal standards that correspond to endogenous peptides created during the enzymatic digestion of the sample of interest. When combined, the endogenous and synthetic peptides elute together chromatographically and ionize with the same efficiency. Since the quantity of the labelled peptide is known, the absolute quantity of the targeted native protein can be determined by comparing MRM hPTP/endogenous peak areas. The precision and utility of this highly sensitive multiplexed method has been demonstrated on undepleted/unenriched plasma for the detection of a panel of human cardiovascular disease and cancer biomarkers with a detection capability of four orders of magnitude (10⁻⁴–10⁴ range in protein concentration) and up to femtomolar level sensitivity in plasma. Recently, a panel of 136 cancer candidate biomarkers was interrogated in unenriched urine samples using MRM, revealing detection limits of up to 25 picogram/ml urine.
With regards to infectious disease biomarker studies, MS-based approaches identified candidate biomarkers in urine for *Leishmania* sp.\(^7\), which has led to the development of a urine capture ELISA diagnostic test\(^8\). Considerable progress has also been made in *Mycobacterium tuberculosis*\(^9-11\) biomarker studies; recent advancements include the detection of *M. tuberculosis* in urine using IgG capture, immunodepletion and MRM methods\(^12\) and MRM assay of exosomes isolated from serum samples from patients with tuberculosis\(^13\).

In this study, we investigated if *T. pallidum* proteins could be detected in plasma and urine samples from individuals with syphilis using a targeted proteomics (MRM) approach. Successful development of a *T. pallidum* antigen test will most likely be contingent upon the simultaneous detection of multiple protein biomarkers to comprehensively cover different stages of disease. Eleven *T. pallidum* protein biomarkers were chosen based on a predicted specificity, high predicted abundance, and physiochemical properties. Thirty surrogate hPTPs were synthesized corresponding to eleven candidate *T. pallidum* biomarkers. Analysis of eighteen plasma and four urine samples revealed no detectable MRM signal for the endogenous peptides from the biomarkers of interest. This is likely due to the extremely low (femtomoles per liter) predicted concentration of bacterial proteins in the samples of interest, or the fact that the biomarkers are not expressed during infection. *T. pallidum* spiking experiments established a MS detection limit of 300 bacteria/ml in PBS; polyclonal anti-*T. pallidum* magnetic bead enrichment did not improve the protein detectability.

**Methods**

**Study participants**

Between January 2014 and August 2015, 120 patients attending the Institute of Tropical Medicine Antwerp clinic, over the age of 17 years, and in whom a new diagnosis of syphilis was made and had not received antibiotics in the preceding thirty days, were recruited into the cohort study. Thirty HIV-positive controls, in whom the diagnosis of syphilis was excluded via serological and PCR testing, were also recruited. The diagnosis and staging of syphilis was according to the Centers for Disease Control and Prevention classification\(^14\), and treatment was administered according to European guidelines\(^14\). All patient sera were tested for syphilis using a RPR test (BD Macro-Vue RPR card test, Becton, Dickinson and Co., Sparks, MD, United States of America (USA)) and an antibody detection *Treponema pallidum* Particle Agglutination test (SERODIA-TPPA Fujirebio Inc., Tokyo, Japan). A PCR test targeting *T. pallidum* polA was also performed on serum\(^15\) and whole blood samples were tested for multiple gene targets\(^16\), as previously described. Selection criteria of participants from the cohort study for the MRM assay analysis included a range of syphilis clinical stages and prioritized predicted high bacterial loads, as demonstrated by positive PCR tests and/or high RPR titres. Patients with early stage syphilis (primary, secondary, early latent) that were plasma and/or whole blood PCR positive for *T. pallidum* were expected to have the highest bacterial load\(^16,17\).

**Plasma and urine sample processing**

Plasma was collected immediately before Benzathine Penicillin G intramuscular injection using 7.5 ml EDTA-coated blood collection tubes (Sarstedt Monovette, Nümbrecht, Germany). We refer to these samples as the *pre-penicillin* samples. A selection of randomly selected patients participated in an additional blood draw three hours after penicillin treatment since studies have shown penicillin to be fast acting on *T. pallidum*, leading to consequent cell lysis and antigen release\(^18\). These samples are termed the *post-penicillin* samples. Plasma was chosen for the MRM assay according to HUPO guidelines\(^19\). Protease inhibitors were not added to the plasma samples since previous studies did not demonstrate a significant higher protein yield with treated samples\(^20\) and peptides could inadvertently be modified\(^20\). Plasma were subjected to dual centrifugation in an Eppendorf 22331 centrifuge (Hamburg, Germany) in an effort to minimize cellular contamination: whole blood was centrifuged at 2000 g for 10 minutes at ambient temperature, followed by transfer of the plasma fraction to a 50 ml falcon tube and centrifugation at 2400 g for 15 minutes. All plasma were processed and aliquoted into cryovials for storage at -80 °C in a long-term freezer unit (Eppendorf U725-G Innova New Brunswick, Hamburg, Germany) until further testing. Mid-stream random-void urine samples were collected and processed following HUPO guidelines\(^4\), including centrifugation for 10 minutes at 2000 g at ambient temperature in order to remove insoluble contents such as cells and casts. Urine was aliquoted into 15 ml falcon tubes and stored at -80 °C until further testing. All plasma and urine samples were processed within three hours of collection and were only subjected to one freeze thaw cycle.

**T. pallidum protein biomarker selection**

In a previous descriptive study we used non-gel based complementary MS techniques to characterize the proteome of *in vivo* rabbit cultured *T. pallidum*\(^21\). Candidate *T. pallidum* biomarker proteins for the MRM assay were chosen based on the following specific criteria: relative protein abundance (based on semi-quantitative spectral counting techniques\(^22\)), Clusters of Orthologous Groups (COG) functional categorization, microarray transcriptome data\(^23\), protein size, physicochemical properties (i.e. previously detected by MS), predicted subcellular localization\(^24\) and literature review. Each of the candidate biomarkers were digested in *silo* by subjecting the FASTA-formatted sequences to tryptic digestion, assuming 100 % digestion efficiency. Proteotypic peptides (PTPs) corresponding to these proteins were determined using ESPPredictor\(^25\) and pBLAST\(^26\); analysis of the protein and PTPs was performed to determine possible homology with other bacterial species and human proteins. After PTP selection was finalized, isotopically labelled synthetic peptide standards (hPTPs) corresponding to these proteins were determined using ESPPredictor\(^25\) and pBLAST\(^26\); analysis of the protein and PTPs was performed to determine possible homology with other bacterial species and human proteins. After PTP selection was finalized, isotopically labelled synthetic peptide standards (hPTPs) corresponding to the selected PTPs were synthesized (Heavy Peptide™ *AQUA* Basic with > 95 % purity; Thermo Fisher Scientific, Ulm, Germany).

**Plasma and urine sample preparation for MRM assay analysis**

Protein concentrations of urine and plasma samples were determined based on the area under curve at 214 nm using a RP-C4 column (Vydac 214TP5415; 4.6x150 mm, particle size 5 μm; Alltech Associates Inc., Lokeren, Belgium) coupled to an Alliance e2695 HPLC system equipped with a 996 PDA detector (Waters Corporation, Milford, MA, USA). For each sample, 230 μg of protein was precipitated by adding six volumes of ice cold LC-MS grade acetone (Biosolve, Valkenswaard, the Netherlands).
followed by overnight incubation in freezer unit (Liebherr, Bulle, Switzerland) at -20 °C. In all cases, lo-bind Eppendorf tubes (Eppendorf, Hamburg, Germany) were used to ensure high recovery rates of proteins and peptides. Protein pellets were re-suspended in 50 mM Tris-HCl/ M urea/5 mM dithiothreitol /10 % beta-mercaptoethanol (25 μL/100 μg protein) at pH 8.7. For the denaturation and reduction process all samples were incubated at 65 °C in a hot water bath for 1 hour. Subsequently, proteins in all fractions were diluted in 50 mM Tris-HCl/ 1 mM CaCl	extsubscript{2} (75 μL/100 μg protein) and alkylated by adding 200 nM iodoacetamide (10 μL/100 μg protein) during 1 hour at ambient temperature and protected from light. Protems were modified tryptic digestion (Promega, Madison, WI, US) was added at a 30:1 protein-to-enzyme ratio. After incubation at 37 °C in a hot water bath for 18 hours the digestion was stopped by freezing the samples. Protein digests were desalted by SPE using GracePure SPE C18-Max (50 mg) (W. R. Grace & Co., Columbia, MD, US) RP cartridges and a vacuum manifold. SPE cartridges were conditioned with 100 % methanol and equilibrated with 100 % LC/MS grade H	extsubscript{2}O and 0.1 % formic acid (FA). After loading the complete acidified (0.1 % FA) tryptic digest, peptides were washed with 10 % methanol and eluted with 40 % methanol/ 40 % acetonitrile (ACN) and 0.1 % FA. Eluted peptides were lyophilized and frozen at -20 °C until further analysis. Immediately before analysis, lyophilized digests were resuspended in 5 % ACN/0.1 % FA and spiked with a mixture of all hPTPs.

**MRM assay optimization and mass spectrometric analysis**

Optimization of each PTP was performed on a triple quadruple mass spectrometer (Waters Xevo TQ, Waters Corporation, Milford, MA, US) in order to obtain the most intense transitions. The capillary voltage was tuned to approximately 2 kV with a source temperature of 150 °C. Desolvation temperature was set at 400 °C with a nitrogen gas flow of 800 L/h. Cone voltage, collision energy and dwell times were optimized for each of the PTPs. All PTPs were dissolved in mobile phase A (MP-A), containing 5 % ACN (LC/MS grade) and 0.1 % FA. For each of the peptides individually, the Limit of Detection (LOD) was determined by performing a dilution series in MP-A. Based on these concentrations, a mixture of all hPTPs was made. A balanced hPTP mixture has been shown to increase quantification accuracy and reproducibility compared to an equimolar mixture in previous studies. To check for possible suppressive effects of the plasma matrix, the hPTP mixture was spiked into plasma from a control study subject. A balanced mixture of hPTP (concentrations detailed in Supplementary File 1) was spiked into 50 μg of plasma digest. Chromatographic separation of the plasma and urine samples was performed on a RP-C18 UPLC column (Waters, CSH 150 × 2.1 mm, 1.7 μm at 35 °C) connected to an Acquity UPLC system (Waters Corporation, Milford, MA, US). In order to separate all peptides as best as possible, an optimized linear gradient of Mobile Phase B (MP-B) (0.1 % FA in 100 % ACN) was applied: 5 % MP-B during 1 min and from 5 to 35 % MP-B in 5 min, followed by a steep increase to 100 % MP-B in 1 min, all at a flow rate of 300 μL/min. Based on the specific retention times of each peptide, three scheduled MRM runs of 10 minutes were generated, each of them containing 20 MS1 channels (10 endogenous **(T. pallidum)** PTPs without isotopic label and 10 channels with a synthetic hPTP equivalent). At least three transitions (ion pairs) were selected for each peptide of interest. For each scheduled MRM analysis, 50 μg of peptides (injection loop of 5 μL) plasma/urine sample were loaded onto the analytical column. In addition to an extensive needle wash after each injection, a blank run was performed between two subsequent clinical samples to prevent carry-over effects. Data acquisition was controlled by MassLynx version 4.1, while targeted datasets were analysed by TargetLynx, which is part of MassLynx (Waters Corporation, Milford, MA, USA). All Xevo TQ MS raw spectral files are available at PeptideAtlas with the identifier PASS00978.

**Magnetic bead antibody-based enrichment of **(T. pallidum) **proteins and approximation of the MS LOD for **(T. pallidum) **protein detection**

**(T. pallidum) protein enrichment was performed using magnetic beads (Dynabeads® M-270, Life Technologies, CA, USA) coated with biotin-conjugated polyclonal **(T. pallidum)-specific antibodies (PAI-73103, Thermo Fisher Scientific, CA, USA) through streptavidin-biotin conjugation. According to the manufacturer’s protocol, 10 μg of antibody was used to bind 1 mg of beads (approximately 5 × 10⁷ beads).**

In **in vivo** rabbit cultured purified **T. pallidum** DAL-1 strain extracts were kindly provided by the group of David Šmajs from the Masaryk University, Czech Republic. The original concentration of the **T. pallidum** extract was approximately 10⁶ bacteria/ml as quantified under darkfield microscopy using an Olympus BX41 (Olympus Corporation, Tokyo, Japan) equipped with darkfield microscope condenser DCW 1.4-1.2; magnification 10×40. Samples were stored in 1 ml phosphate buffered saline (PBS) and only subjected to one freeze-thaw cycle. Two dilution series of **T. pallidum** were prepared, each time starting in 1 ml of PBS and finally equating to eight approximate bacterial concentrations: 10⁷, 10⁶, 300, 100, 33, 10, 3 and 0 bacteria/ml.

For one dilution series, each of the eight fractions were incubated with a constant amount (~10⁴) of magnetic beads coated with polyclonal anti-**(T. pallidum)** antibodies. After incubation for two hours at 4° C and magnetic separation, the supernatant was discarded and beads were washed three times with PBS. To lyse the antibody bound bacteria, 1 ml of PBS was added to each bead sample, these were sonicated on ice using a Sonics Vibra Cell VC130 (Sonics and Materials Inc., Newtown, CT, USA) (two times 30 seconds with an amplitude of 50 %). The bead fraction was retained (retentant) after sonication by using magnetic separation. Released proteins were precipitated adding ice-cold acetone and incubated overnight at -20 °C. Tryptic digestion was performed, following the aforementioned procedure, on both the precipitated proteins (supernatant) and directly “on-bead” (retentate), to test for possible unreleased proteins during sonication. For the second dilution series (unenriched), 1 ml was directly drawn from each of the eight samples. The samples from this series were also sonicated on ice (two times 30 seconds with an amplitude of 50 %) to lyse the bacteria. Released proteins were then acetone precipitated and subsequently digested, in conformance with the other parallel series procedure.
Liquid chromatography-electrospray ionization-LTQ-Orbitrap mass spectrometry analysis of enriched and non-enriched serially diluted *T. pallidum* samples

Peptide mixtures were separated by RPLC on a Waters nano-UPLC system using a nanoACQUITY BEH C18 Trap column (100 Å, 5 μm, 180 μm × 20 mm) connected to a nanoACQUITY BEH C18 analytical Column (130 Å, 1.7 μm, 100 μm × 100 mm) (Waters Corporation, Milford, MA, USA). Peptides were dissolved in MP-A, containing 2 % ACN and 0.1 % FA and spiked with 20 fmol [Glu1]-fibrinopeptide B, which serves as an internal calibrant. A linear gradient of MP-B (0.1 % FA in 98 % ACN) from 2 to 45 % MP-B in 45 min, followed by a steep increase to 95 % MP-B in 2 min at a flow rate of 400 nl/min. The nano-LC was coupled online with a LTQ Orbitrap Velos (Thermo Scientific, San Jose, CA, US) mass spectrometer using a PicoTip Emitter (New Objective, Woburn, MA, US) linked to a nanospray ion source. The mass spectrometer was set up in a data dependent acquisition MS/MS mode where a full scan spectrum (350–2500 m/z, resolution of 60.000) was followed by a maximum of ten CID tandem mass spectra (100 to 2000 m/z). Peptide ions were selected as the twenty most intense peaks of the MS scan. CID scans were acquired in the LTQ ion trap part of the mass spectrometer with normalized collision energy of 32 %.

Obtained spectra were screened against the *T. pallidum* reference and resequenced databases (UniProt ID proteome UP000014259\(^{15}\) and UP000000811\(^{15}\) using the MASCOT search engine (Matrix Science; version 2.1.03) based on the digestion enzyme trypsin. Carbamidomethylation of cysteines was listed as a fixed modification, while methionine oxidation was set as a variable modification. A maximum of one missed cleavage was tolerated. Mass tolerance was set to 10 ppm for the precursors and 0.8 Da for the fragment ions. False discovery rate was set at 5 %. Scaffold Q+ (version 4.6.2, Proteome Software Inc., Portland, OR, US) was used to validate MS/MS-based peptide and protein identifications. Protein identifications were accepted if they could be established at greater than 95.0 % probability according to the protein prophet algorithm\(^{16}\).

All LTQ-Orbitrap MS/MS raw spectral data is available at PeptideAtlas\(^{14}\) with the identifier PASS00978.

**Results**

**Study subject inclusion**

Eighteen syphilis-infected study participants were selected for the MRM assay analyses (Table 1). All participants were male and identified as MSM. A third of the participants (6/18; 33 %) were treated with intramuscular injection with 2.4 MU Benzathine penicillin G; Indet.- indeterminate PCR result, second confirmatory PCR was not performed; ND- not done.

---

**Table 1. Summary of the clinical and laboratory characteristics of study subjects included in this study.**

| Patient Number | HIV status | Syphilis stage | Sample type | Pre or post-treatment sampling* | PCR Whole Blood | PCR Serum | RPR titre | TPPA titre |
|---------------|------------|---------------|-------------|-------------------------------|----------------|----------|-----------|------------|
| 1             | Positive   | Secondary     | Plasma      | Pre                           | Positive       | Indet.    | >1/20480 |            |
| 2             | Negative   | Primary       | Plasma      | Pre                           | Negative       | 1/4       | 1/160     |            |
| 3             | Positive   | Early latent  | Plasma      | Pre                           | Negative       | Positive  | 1/1280    | >1/20480   |
| 4             | Positive   | Secondary     | Plasma      | Pre                           | Positive       | 1/128     | 1/20480   |            |
| 5             | Positive   | Secondary     | Plasma      | Pre                           | Positive       | 1/128     | >1/20480  |            |
| 6             | Negative   | Secondary     | Plasma      | Pre                           | Negative       | Positive  | 1/128     | >1/20480   |
| 7             | Positive   | Early Latent  | Plasma      | Pre                           | Positive       | 1/64      | 1/10240   |            |
| 8             | Positive   | Secondary     | Plasma      | Pre                           | Positive       | Indet.    | 1/32      | 1/1280     |
| 9             | Positive   | Secondary     | Urine       | Pre                           | Positive       | 1/512     | >1/20480  |            |
| 10            | Negative   | Primary       | Plasma      | Pre                           | Positive       | Indet.    | 1/16      | 1/5120     |
| 11            | Positive   | Secondary     | Urine       | Pre                           | ND             | Indet.    | 1/128     | >1/20480   |
| 12            | Negative   | Secondary     | Plasma      | Pre                           | Positive       | Negative  | 1/32      | >1/20480   |
| 13            | Positive   | Secondary     | Plasma      | Post                          | ND             | Indet.    | 1/128     | >1/20480   |
| 14            | Negative   | Primary       | Urine       | Post                          | Positive       | Indet.    | 1/16      | 1/5120     |
| 15            | Negative   | Primary       | Plasma      | Post                          | Positive       | Indet.    | 1/8       | 1/1280     |
| 16            | Positive   | Secondary     | Plasma      | Post                          | Positive       | Negative  | 1/64      | 1/20480    |
| 17            | Positive   | Primary       | Plasma      | Post                          | Positive       | Negative  | 1/64      | >1/20480   |
| 18            | Positive   | Secondary     | Plasma      | Post                          | Negative       | 1/128     | >1/20480  |            |

Legend: *- patients were treated with intramuscular injection with 2.4 MU Benzathine penicillin G; Indet.- indeterminate PCR result, second confirmatory PCR was not performed; ND- not done
were HIV positive. Five (28%) presented with primary, eleven secondary (61%), and two early latent (11%) stage disease. Thirteen participants were confirmed *T. pallidum*-positive by serum and/or whole blood PCR testing. Four participants had indeterminate PCR results, meaning their sample was weakly positive. A second confirmatory PCR was not performed on these samples. One patient was negative for both whole blood and serum PCR. All participants tested positive with both the RPR and TPFA tests. The median RPR value was 1/64 (Interquartile range (IQR): 1/16- 1/128). In total, 22 samples were analysed, including N = 12 pre-penicillin treatment plasma, N = 6 post-penicillin treatment plasma and N = 4 pre-penicillin treatment urine samples.

**T. pallidum** protein biomarker selection

Eleven *T. pallidum* proteins were selected as candidate biomarkers (Table 2). Most selected biomarkers had high normalized spectral abundance factor (NSAF) scores according to our previous study (median 4.02; IQR: 1.97-6.97) and high microarray signal ratios (median 3.05; IQR: 0.74-6.8). The median protein molecular weight was 39 kDa (IQR: 28-81). Two proteins were predicted to be located in the flagellum (TP_0249 and TP_0792), two in the ribosome (TP_0250b and TP_0244) and the subcellular localization of five proteins was unknown. Protein TP_0326, a BamA orthologue, has been experimentally shown to be localized in the outer membrane. A typical target for PCR assays is polA, coding protein TP_0105. One protein, Peptidyl-prolyl cis-trans isomerase (TP_0862) was found in a previous proteomics study where it demonstrated moderate reactivity during immunoblot experiments with human and rabbit *T. pallidum* infected serum. Protein TprG (TP_0317) is part of the paralogous tpr gene family that encodes candidate virulence factors and is partially homologous to TprE/J. According to pBLAST analysis, all chosen biomarker proteins and corresponding PTPs did not demonstrate high homology with other pathogens, non-pathogenic commensal bacterial or human proteins (data not shown). One to three corresponding well-suited PTPs were selected for each biomarker, for a total of 30 PTPs. Details pertaining to these are provided in Table 2.

**Multiple reaction monitoring assay optimization**

The LOD for each peptide was determined individually by performing a dilution series of MP-A whereby the median LOD was 68.5 (IQR 14.2-176.7) picomoles. Once the peptide spiking dilution series were prepared in PBS and subjected to LTQ-Orbitrap MS/MS analysis in order to estimate the LOD of MS detection. One of the series was subjected to an additional polyclonal antibody coupled magnetic bead enrichment step, including sonication of the beads and subsequent separate measurement of the lysate and on-bead digestion retentate (Figure 2).

Two unique *T. pallidum* proteins, Cytoplasmic filament protein A (TP_0748) and Lipoprotein antigen Tp47 (TP_0574), were found in the 300 bacteria/ml fraction in the enriched and unenriched samples, respectively (Figure 3; Supplementary File 3). Therefore, the LOD based on a high-resolution LTQ-Orbitrap instrument was approximately 300 bacteria/ml PBS for both the antibody enriched and unenriched samples, meaning there was no significant improvement in LOD using bead enrichment. No proteins were detected in any sample concentrations for the enriched bacterial lysate (supernatant) fraction. Possibly, the sonication conditions were not harsh enough to lyse the bacteria on the beads and lysis was mainly the results of trypsin treatment under denaturing conditions. In total, eight unique *T. pallidum* proteins were found in both the unenriched and enriched retentate dilution series in one or more of the concentrations analyzed: 60 kDa chaperonin (TP_0030), Flagellar filament outer layer protein flaA1 (TP_0249), Alkyl hydroperoxide reductase (TP_0509), Lipoprotein antigen Tp47 (TP_0574), Galactose ABC superfamily ATP binding cassette transporter, binding protein (TP_0684), Cytoplasmic filament protein A (TP_0748) and the Flagellar filament core proteins flaB1/B3 (TP_0792/TP_0870). Four proteins, Lipoprotein, 15 kDa (TP_0171), 10 kDa chaperonin (TP_1013), Elongation factor Tu (TP_0187) and Tp34 lipoprotein (TP_0971) were only found in the unenriched and enriched series, respectively. Ten unique *T. pallidum* proteins were found in the highest concentration (10¹ bacteria/ml) for in the enriched retentate sample (N = 10) and non-enriched sample (N = 10), two proteins detected were unique to either the enriched or unenriched samples (Figure 3). Five unique *T. pallidum* proteins were found in the 10³ bacteria/ml sample, including N = 4 in the unenriched and N = 4 in the retentate fractions. A peptide (LSGGVAVIK) related to 60 kDa chaperonin (TP_0030) was detected in the low concentration (10⁰/ 3/ 10/ 3 bacteria/ml) and in the negative control samples of the enriched sample series. This was likely a false-positive non-specific peptide secondary to rabbit protein contamination since this short peptide sequence is closely homologous to the *Oryctolagus cuniculus* (rabbit) 60 kDa heat shock protein, or could have originated from the beads or antibodies. As a result, it has been excluded from the analysis. Three *T. pallidum* proteins detected in both the enriched and unenriched sample series were also biomarker candidates tested in the MRM assay experiments: Flagellar filament core protein...
| Number | UniProt Accession Number | TP Number/ gene | Protein Name | Peptide Number | Peptide Sequence | Protein Weight (kDa) | Predicted Subcellular Location | COG category function | Spectral Count NSAF value in T. pallidum | cDNA/DNA signal ratio |
|--------|--------------------------|----------------|-------------|----------------|-----------------|---------------------|-------------------------------|----------------------|---------------------------------|---------------------|
| 1      | R9US76                   | TP_0105/pola    | DNA-directed DNA polymerase | 16             | TSAVSGAIP1ENR   | 112                | NK                           | L                    | 2.55                            | 0.283               |
| 2      | O83346                   | TP_0326/tp92   | Putative outer membrane protein assembly factor | 17             | MALTQIQSSAADVYK |                     |                               |                      |                                 |                     |
| 3      | R9UVD9                   | TP_0249/ flaA   | Flagellar filament outer layer protein | 18             | VHTSFVQIGTATGR  | 94                 | Outer Membrane               | M                    | 1.77                            | 0.682               |
| 4      | O83834                   | TP_0982/lkB    | Peptidyl-prolyl cis-trans isomerase | 19             | TEAGGVVWQFTDQEGK |                     |                               |                      |                                 |                     |
| 5      | O83892                   | TP_0992        | Uncharacterized Protein | 20             | EQWASSPGLAESFK  |                     |                               |                      |                                 |                     |
| 6      | R9USJ3                   | TP_0250/rpsT   | 30S ribosomal protein S20 | 21             | LAFANFTSPGQP    |                     |                               |                      |                                 |                     |
| 7      | R9UU30                   | TP_0244/rpsG   | 30S ribosomal protein S7 | 22             | LATEGFTGPSGQAQR |                     |                               |                      |                                 |                     |
| 8      | O83337                   | TP_0317        | Tpr protein G | 23             | DESLQDFAK       |                     |                               |                      |                                 |                     |
| 9      | P21991                   | TP_0792/flagA  | Flagellar filament core protein FlaB | 24             | GTLLDGTVFADSR   |                     |                               |                      |                                 |                     |
| 10     | R9UTS8                   | TP_0748/cpa/tpn83 | Cytoplasmic filament protein A | 25             | KPGQVTSSQGLQEVVK |                     |                               |                      |                                 |                     |
| 11     | O83417                   | TP_0402/flagG  | IIISP family Type III (Virulence-related) secretory pathway protein/Flagellum-specific ATP synthase | 26             | FYVPSLGYG1R     |                     |                               |                      |                                 |                     |

Legend: *- UniProt proteome ID UP000014259; &- ORF was not annotated in the re-sequenced Nichols strain genome due to its length below the 150 bp limit; @- underlined/bold amino acids indicate stable isotope labelled residues; $- peptide is homologous in Tpr E/G/J protein sequences; ¥- subcellular location as reported in Osbak et al.¹; NK- not known; NSAF- normalized spectral abundance factor; COG- clusters of orthologous groups; COG categories: L- Replication, recombination and repair; M- Cell wall/membrane/envelope biogenesis; N- Cell motility; O- Posttranslational modification, protein turnover, chaperones; J- Translation, ribosomal structure and biogenesis; S- Function unknown; U- Intracellular trafficking, secretion, and vesicular transport.
Figure 1. Intensity plots displaying MRM experiments on plasma from an individual with secondary stage syphilis. (a) synthetic hPTPs, even numbers and (b) endogenous (T. pallidum) PTPs, odd numbers; gradient 1 of 3. For each peptide the number of selected transitions (channels) is reported. The x-axis shows the chromatographic retention time of the corresponding peptide while the y-axis shows the relative intensity of the MS2 signal. Note: Signal fluctuations present in the ‘endogenous’ PTP chromatogram are always the result of just one transition, often coupled with a shift in retention time and differing m/z-values differ from the hPTP run, thus these are considered to be noise.
**Figure 2.** Work-flow diagram describing the estimation of *T. pallidum* protein MS LOD experiments. In total, eight different concentrations of *T. pallidum* (from $10^4$ to 0 bacteria/ml PBS) were treated in three different ways: i) *T. pallidum* was enriched using magnetic beads coated with polyclonal anti-*T. pallidum* antibodies and lysed by sonication for release of *T. pallidum* proteins in the supernatant. Acetone precipitated proteins were trypsinized; ii) In order to detect any remaining protein on the beads, the beads were also trypsinized (retentant on-bead trypsinization); iii) As a control, non-enriched samples were sonicated and immediately trypsinized. *-*proteins selected as candidate biomarkers in this study. All samples were analysed by an LTQ-Orbitrap mass spectrometer.

**Figure 3.** *T. pallidum* proteins detected in LOD magnetic bead coupled polyclonal anti-*T. pallidum* antibody enrichment experiments (protein and peptide identification threshold of 95 %). *-*proteins selected as candidate biomarkers in this study.
flaB2 (TP_0792), Cytoplasmic filament protein A (TP_0748) and the Flagellar filament outer layer protein flaA1 (TP_0249). Detailed information about the identified proteins, peptides, coverage and search parameters can be found in Supplementary File 3. Rough concentration calculations estimated that our target PTPs would be present in the femtomoles per liter range in human T. pallidum infection (calculations presented in Supplementary File 4).

Discussion
The T. pallidum MRM assay designed in this study failed to detect any of the 30 targeted proteotypic peptides related to eleven candidate T. pallidum protein biomarkers in eighteen plasma and four urine samples from individuals with syphilis. A number of explanations are possible. The foremost is the extremely low predicted concentration of bacterial proteins compared to host proteins. To a large extent our estimates of T. pallidum bacterial load in blood are based on molecular studies. In one of the largest studies, Tipple et al. found that median copy numbers of Lipoprotein antigen Tp47 (TP_0574) DNA detectable per milliliter of whole blood was 127, 516 and 70 in primary, secondary and latent syphilis, respectively. Other studies have produced comparable results, with the exception of a recent study that found a median of 1.4 x 10^8 T. pallidum/ml in whole blood from patients with secondary syphilis.

The concentration of T. pallidum in blood according to these PCR-based studies is lower compared to our estimated LOD in a shotgun experiment on diluted samples (300 T. pallidum/ml) since we would need a 500x higher concentration (same amount of proteins from 300 T. pallidum in 1 ml vs. 2 μl) to detect the 300 T. pallidum/ml (see Supplementary File 4). Despite this outcome, we were hoping to detect T. pallidum proteins in the plasma or urine of some syphilis patients because i) MRM measurements are generally more sensitive than shotgun experiments since scanning times are drastically reduced and ii) the amounts from Tipple et al. were averages so we hypothesized that some patients (especially those with secondary syphilis) might have high T. pallidum levels detectable by MRM. These results could then motivate us to develop an (immuno)assay, capable of detecting the proteins even at low concentrations.

Little difference in T. pallidum abundance has been found between whole blood, plasma or serum. Not much is known about the persistence of T. pallidum in the human urinary tract and to our knowledge no studies have quantified T. pallidum in the urine of syphilis-infected patients. However, even if T. pallidum does not consistently persist in the urinary tract, bacterial proteins present in the blood could be filtered through the glomerulus, ending up in the urine either intact or as peptide fragments, depending on the size of the protein and state of proteolysis.

These considerations suggest that detection of T. pallidum proteins in human biofluids may not be possible without additional steps such as front-end immunoaffinity depletion, two-dimensional LC separation and/or selective enrichment of target proteins/peptides (as reviewed by Shi et al.). These techniques, or combinations thereof, have allowed the detection of low abundance proteins up to the low- to sub-nanogram/ml level in clinical samples. For example, to reduce the wide dynamic range of plasma proteins, multicomponent single-step immunoaffinity depletion of high-abundant (host) proteins can allow up to a 10-20-fold enrichment of low-abundant proteins due to the depletion of 90–95% of the total protein mass. However, of particular concern with this approach is the possibility of concomitant removal of low-abundance proteins due to protein binding to the antibodies or high-abundant proteins, as shown in a study that systematically analysed the antibody bound (high-abundant) protein fraction which found that this fraction contained 101 proteins at a high degree of confidence. T. pallidum has a high binding affinity for constituents of serum and host cells, including laminin, fibronectin and albumin, which may lead to unintentional depletion of targeted proteins if human protein specific immunodepletion would be applied. Furthermore, targeted mass spectrometric immunoassays (MSIA) that use surface-immobilized antibodies to affinity retrieve proteins from biological samples have proven their utility for clinical applications.

In our study, magnet bead coupled polyclonal anti-T. pallidum antibodies failed to significantly detect more T. pallidum proteins compared to the unenriched dilution series. Antibody effectivity is dictated by binding affinity; we used commercial antibodies that were to our knowledge not previously characterized as to their binding affinity or targeted proteins. Furthermore, it is unlikely that the polyclonal antibodies would bind a large range of proteins since few (<5 %) T. pallidum proteins are immunogenic. The fact that T. pallidum can remain in ‘plain sight’ without invoking immune defences, together with the very low amount of outer membrane proteins compared to other human pathogens, also suggests that antibody enrichment of whole organisms and/or proteins would probably not be an effective strategy. Peptide-level immunoenrichment, also known as the ‘Stable Isootope Standards and Capture by Anti-Peptide Antibodies’ (SISCAPA) method developed by Anderson et al. has shown considerable promise as a high-throughput, automated, highly multiplexed approach for protein biomarker quantification, with MRM application detection limits in the low picogram/ml range of protein concentration in plasma. If a selection of T. pallidum peptides could be definitively demonstrated to be present in plasma or urine, then this could be an attractive analytical approach with a strong potential for yielding the detection capabilities and precision needed for clinical applications.

However, apart from the low abundance in plasma or urine, other factors could explain why the T. pallidum proteins were not detected in our MRM experiments:

1. The LOD T. pallidum spiking experiments were performed in PBS buffer as opposed to a highly complex plasma or urine matrix background.

2. Variations in gene expression and structural components of proteins could also account for the lack of T. pallidum protein detection. Fluctuations in gene expression may explain why we did not find TpR, a protein implicated in phase variation which has been shown to be expressed at varying levels during infection due to changes in the number of guanine nucleotide
repeats immediately upstream of its transcriptional start site\textsuperscript{36}. Heterogeneous \textit{T. pallidum} protein sequence sites\textsuperscript{33,34,36,39} could also confound rigid MRM assay detection parameters. Such heterogeneity has been shown\textsuperscript{37} to be present in one candidate biomarker, TP.0922, although this variable site was not present in the PTPs incorporated in this MRM assay. Poor proteolytic cleavage can stem from structural features of the protein, different digestion kinetics and post-translational modifications. For example, phosphorylated residues within two amino acids of the point of cleavage can hinder proteolysis\textsuperscript{87}. Little is known about the extent of \textit{T. pallidum} protein post-translational modification aside from a study that demonstrated glycosylation of the Flagellar core proteins (FlaBs) as reported by antibody and glycan staining techniques\textsuperscript{86}, however, the exact modification sites and extent of modification remain unknown. Other proteomics studies of \textit{L. interrogans} have demonstrated likely roles for protein acetylation and methylation in virulence mechanisms\textsuperscript{39,40}.

3. We only tested eleven out of more than a thousand predicted proteins in the \textit{T. pallidum} proteome\textsuperscript{87}, a selection largely based on spectral counting\textsuperscript{1} as an estimation of protein abundance. We cannot assume, however, that this indirect manner of quantifying \textit{T. pallidum} protein levels in a rabbit testicle model directly recapitulates \textit{T. pallidum} protein expression levels in plasma samples of syphilis-infected patients. One of the reasons for this is that protein expression may vary according to host and disease stage. Antigen detection during latent stage disease will be especially challenging since \textit{T. pallidum} has been shown to sequester itself in protected niches such as eyes, hair follicles and nerves\textsuperscript{87}. Other \textit{T. pallidum} proteins may be more suitable diagnostic biomarkers, given that they are reflective of the disease stages studied and that they are consistently present in the biofluids of interest. For example, Lipoprotein Tp47, which could still be identified in the most diluted \textit{T. pallidum} sample (300 \textit{T. pallidum}/ml) in this study, could be an interesting biomarker for future studies.

4. Various technical limitations such as a possible suboptimal chromatographic gradient length, modifiable proteotypic residues and protein degradation secondary to sample processing could have impeded biomarker detection. Other studies have reported chromatographic gradient lengths of 30 minutes or longer\textsuperscript{33,34,36,39}, thus implementation of longer gradients could be considered in future studies in order to improve peptide resolution. In this study, chromatographic separations were performed in triple using shorter 10-minute gradients in order to optimize the sample throughput without the loss of MS sensitivity due to overlapping transition windows. Therefore, co-eluting peptides were split over different chromatographic runs since plasma protein availability was not a limiting factor. Oxidizable proteotypic residues, namely cysteine, methionine and tryptophan, can cause artificial modifications during processing or storage resulting multiple forms of targeted peptides. With this said, the PTP selection process also requires a necessary balance between many different parameters, whereby selection of peptides containing suboptimal amino acid residues can sometimes remain the most favourable option. Ribosomal protein TP.0250b was only represented by one PTP, which may have limited detectability, thus future assays could ideally incorporate more than one peptide per protein.

5. Sample processing may have also contributed to protein degradation; therefore prompt analysis of fresh non-frozen biological specimens, if possible, is recommended. Moreover, alternative sample processing procedures, such as the use of molecular weight cut off filters to concentrate urine could improve protein detectability\textsuperscript{40}.

6. Lastly, only a limited amount of clinical samples were analysed, especially urine and the study was a single centre study with only MSM participants, therefore it is not generalizable. An improvement for future studies would be the incorporation of isotopically labelled (non-\textit{T. pallidum}) reference standards, which have been shown to improve analytical precision, detect variations in instrument performance and aid in detecting chemical interferences\textsuperscript{41,42}.

Targeted MS approaches are only able to search for a limited amount of pre-selected biomarker candidates. A more comprehensive approach would be to take a step backwards to conduct broader shotgun proteomics in plasma and urine samples of individuals with syphilis. Shotgun approaches identifying \textit{M. tuberculosis} antigens in urine have been previously successful\textsuperscript{43,44}. A compelling study from Eyford et al. used a ‘deep-mining’ proteomics approach and were able to detect 254 \textit{Trypanosoma brucei rhodesiense} proteins in plasma from African sleeping sickness patients\textsuperscript{45}. Quantitative data-independent acquisition modes of MS analysis, including SWATH-MS\textsuperscript{94}, are also very promising avenues for clinical applications\textsuperscript{95,96}.

\textbf{Conclusions}

In an effort to identify promising \textit{T. pallidum} diagnostic biomarkers, we designed a scheduled MRM assay incorporating 141 MRM ions pairs correlated to 30 PTPs/11 \textit{T. pallidum} proteins. Factors such as the extremely low (femtomoles per liter) predicted \textit{T. pallidum} protein concentration in biofluids, possible variable protein expression according to host/disease stage and potential presence of protein post-translational modifications likely contributed to the lack of signal detection for all candidate biomarkers investigated. Since the proteins targeted in this study were likely buried in the proverbial haystack of plasma proteins, alternative sample preparation and analysis strategies are warranted. With the rapidly progressing innovations of MS applications and technology, we believe clinical proteomics is far from its pinnacle of potential.

\textbf{Data availability}

The datasets supporting the conclusions of this article are available in the PeptideAtlas\textsuperscript{44} repository, with the identifier PASS00978, in addition to being provided within the article and its Supplementary Files.

\textbf{Consent and ethics approval}

The prospective observational cohort study (SeTPAT Clinical-Trials.gov # NCT02059525) that provided the clinical samples...
used in this study was approved by the Institutional Review Board of the Institute of Tropical Medicine Antwerp and the Ethics Committee of the University of Antwerp (13/44/426), Belgium. Written informed consent for publication of the participants’ anonymized details was obtained from the participants. The T. pallidum ssp. pallidum DAL-1 strain used in this study was propagated in rabbits at the Veterinary Research Institute in Brno, Czech Republic. The handling of animals in the study was performed in accordance with the current Czech legislation (Animal Protection and Welfare Act No. 246/1992 Coll. of the Government of the Czech Republic). These specific experiments were approved by the Ethics Committee of the Veterinary Research Institute (Permit Number 20–2014).

Grant information
This work was supported by a grant from the Flanders Research Foundation, SOFI-B Grant (#757003) to CRK, http://www.fwo.be/.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements
Special thanks to the study participants, in addition to David Šmajs and Michal Strouhal (Masaryk University, Brno, Czech Republic) for providing the purified T. pallidum DAL-1 strain used in this study.

Supplementary materials
Supplementary File 1. Table listing of optimized MRM parameters for 30 peptides targeting 11 T. pallidum proteins. (Supplementary File 1.xlsx).

Click here to access the data.

Supplementary File 2. Examples of intensity plots.

Click here to access the data.

Supplementary File 3. Table listing of protein and peptide reports for the LOD experiments using purified T. pallidum dilution series and ESI-LTQ-Orbitrap MS/MS analysis. (Supplementary File 3.xlsx).

Click here to access the data.

Supplementary File 4. Calculations to estimate concentration of T. pallidum proteins corresponding to proteotypic peptides (PTPs) in human syphilis infections. (Supplementary file 4.xlsx).

Click here to access the data.

References
1. Edmundson DG, Hu B, Norris SJ: Long-Term In Vitro Culture of the Syphilis Spirochete Treponema pallidum subsp. pallidum. mBio. 2018; 9(3): pii: e01153-18. PubMed Abstract | Publisher Full Text | Free Full Text
2. Newman L, Rowley J, Vander Hoorn S, et al: Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting. PLoS One. 2015; 10(12): e0143304. PubMed Abstract | Publisher Full Text | Free Full Text
3. Van de Laar M, Spiteri G: Increasing trends of gonorrhoea and syphilis and the threat of drug-resistant gonorrhoea in Europe. Euro Surveill. 2012; 17(29): pii: 200225. PubMed Abstract
4. Peterman TA, Su J, Bernstein KT, et al: Syphilis in the United States: on the rise? Expert Rev Ant Infect Ther. Informa UK, Ltd. 2015; 13(2): 161–8. PubMed Abstract | Publisher Full Text
5. Kenyon C, Lynen L, Florence E, et al: Syphilis reinfections pose problems for syphilis diagnosis in Antwerp, Belgium - 1992 to 2012. Euro Surveill. 2014; 19(45): 20958. PubMed Abstract | Publisher Full Text
6. Ogilvie GS, Taylor DL, Moniruzzaman A, et al: A population-based study of infectious syphilis rediagnosis in British Columbia, 1995-2005. Clin Infect Dis. 2009; 49(11): 1554–8. PubMed Abstract | Publisher Full Text
7. Sefia AC, White BL, Sairling PF: Novel Treponema pallidum serologic tests: a paradigm shift in syphilis screening for the 21st century. Clin Infect Dis. Oxford University Press; 2010; 51(6): 790–8. PubMed Abstract | Publisher Full Text
8. Belisle JT, Brandt ME, Radolf JD, et al: Fatty acids of Treponema pallidum and Borrelia burgdorferi lipoproteins. J Bacteriol. 1994; 176(8): 2151–7. PubMed Abstract | Publisher Full Text | Free Full Text
9. Joyanes P, Borobio MV, Arquez JM, et al: The association of false-positive rapid plasma reagin results and HIV infection. Sex Transm Dis. 1998; 25(10): 569–71. PubMed Abstract | Publisher Full Text
10. Monath TP, Frey SE: Possible autoimmune reactions following smallpox vaccination: the biologic false positive test for syphilis. Vaccine. 2009; 27(10): 1645–50. PubMed Abstract | Publisher Full Text
11. Seña AC, Wolff M, Martin DH, et al: Predictors of serological cure and Serofast State after treatment in HIV-negative persons with early syphilis. Clin Infect Dis. Oxford University Press; 2011; 53(11): 1092–9. PubMed Abstract | Publisher Full Text | Free Full Text
12. Gayet-Ageron A, Lautenschlager S, Nitin B, et al: Sensitivity, specificity and
likelihood ratios of PCR in the diagnosis of syphilis: a systematic review and meta-analysis. Sex Transm Infect. 2013; 89(3): 251–6. 

36. Kuzyk MA, Smith D, Yang J, et al.: Multiple reaction monitoring-based, multiplexed, absolute quantitation of 46 proteins in human plasma. Mol Cell Proteomics. 2009; 8(8): 1860–77. 

37. Pereira AJ, Yang J, Hardie DB, et al.: Precise quantitation of 136 urinary proteins by LC/MS/MS using stable isotope labeled peptides as internal standards for biomarker discovery and/or verification studies. Methods. Elsevier Inc.; 2015; 81: 24–33. 

38. Abeijon C, Kashiho SS, Silva FO, et al.: Identification and diagnostic utility of Leishmania infantum proteins found in urine samples from patients with visceral leishmaniasis. Clin Vaccine Immunol. 2012; 19(6): 935–43. 

39. Merkel MA, Edmondson DG, Carroll JA, et al.: Characterizing the Syphilis-Causing Treponema pallidum strain: published Proteome Using Comprehensive Mass Spectrometry. PLoS Negl Trop Dis 2016; 10(9): e0004988. 

40. Flasarová M, Pospíšilová P, Mikalová L, et al.: Characterization and serologic analysis of the Treponema pallidum proteome. Infect Immun. 2010; 78(6): 2631–4. 

41. Voir D, Mallender M, Pérez G, et al.: Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay, HpSA European study group. Lancet. 1999; 354(9172): 30–3. 

42. Jarvis JN, Percival A, Bauman S, et al.: Assessment of the kinetics of PCR in the diagnosis of syphilis: a systematic review and meta-analysis of the published literature. J Clin Microbiol. 1999; 37(7): 1963–5. 

43. Haque R, Ali IK, Akther S, et al.: Comparison of PCR, isoenzyme analysis, and antigen detection for diagnosis of Entamoeba histolytica infection. J Clin Microbiol. 1998; 36(2): 443–4. 

44. Cross RW, Boisen ML, Millet MM, et al.: Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection. J Infect Dis. 2016; 214(suppl 3): S120–7. 

45. Flores LL, Steingart KR, Dendukuri N, et al.: Precise quantitation of 136 urinary proteins by LC/MS/MS using stable isotope labeled peptides as internal standards for biomarker discovery and/or verification studies. Methods. Elsevier Inc.; 2015; 81: 24–33. 

46. Kashino SS, Pollock N, Napolitano DR, et al.: Characterization and identification of Mycobacterium tuberculosis antigens in urine of patients with active pulmonary tuberculosis: an innovative and alternative approach of antigen discovery of useful microbial molecules. Clin Exp Immunol. Wiley-Blackwell; 2008; 153(1): 56–62. 

47. Kim SH, Lee NE, Lee JS, et al.: Identification of Mycobacterial Antigens in Human Urine by Use of Immunoglobulin G isolated from Sera of Patients with Active Pulmonary Tuberculosis. Land GA, editor. J Clin Microbiol. 2016; 54(6): 1631–7. 

48. Mesias D, McKeivit M, Howell JK, et al.: Transcriptome of Treponema pallidum: gene expression profile during experimental rabbit infection. J Bacteriol. American Society for Microbiology; 2005; 187(5): 1866–74. 

49. Salazar JC, Rathi A, Michael NL, et al.: Assessment of the kinetics of Treponema pallidum dissemination into blood and tissues in experimental syphilis by real-time quantitative PCR. Infect Immun. American Society for Microbiology (ASM); 2007; 75(6): 2954–8. 

50. Young BL, Mialma Z, Qaqarna PP, et al.: The identification of tuberculosis biomarkers in human urine samples. Eur Respir J. 2014; 43(6): 1719–29. 

51. Kruh-Garcia NA, Wolfe LM, Chaisson LH, et al.: Detection of Mycobacterium tuberculosis peptides in urine using a new non-invasive antigen-based assay, HpSA European study group. Lancet. 1999; 354(9172): 30–3. 

52. Jarvis JN, Percival A, Bauman S, et al.: Assessment of the kinetics of PCR in the diagnosis of syphilis: a systematic review and meta-analysis of the published literature. J Clin Microbiol. 1999; 37(7): 1963–5. 

53. Haque R, Ali IK, Akther S, et al.: Comparison of PCR, isoenzyme analysis, and antigen detection for diagnosis of Entamoeba histolytica infection. J Clin Microbiol. 1998; 36(2): 443–4. 

54. Cross RW, Boisen ML, Millet MM, et al.: Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection. J Infect Dis. 2016; 214(suppl 3): S120–7. 

55. Kashino SS, Pollock N, Napolitano DR, et al.: Characterization and identification of Mycobacterium tuberculosis antigens in urine of patients with active pulmonary tuberculosis: an innovative and alternative approach of antigen discovery of useful microbial molecules. Clin Exp Immunol. Wiley-Blackwell; 2008; 153(1): 56–62. 

56. Kim SH, Lee NE, Lee JS, et al.: Identification of Mycobacterial Antigens in Human Urine by Use of Immunoglobulin G isolated from Sera of Patients with Active Pulmonary Tuberculosis. Land GA, editor. J Clin Microbiol. 2016; 54(6): 1631–7. 

57. French P, Gombarg M, Janier M, et al.: IUSTI: 2008 European Guidelines on the Management of Syphilis. Int J STD AIDS. 2009; 20(5): 300–9. 

58. Liu H, Rodes B, Chen CY, et al.: New tests for syphilis: rational design of a PCR method for detection of Treponema pallidum in clinical specimens using unique regions of the DNA polymerase gene. J Clin Microbiol. 2001; 39(5): 1494–6. 

59. Flasarová M, Pospíšilová P, Mikalová L, et al.: Sequencing-based molecular typing of Treponema pallidum strains in the Czech Republic: all identified genotypes are related to the sequence of the SS14 strain. Acta Derm Venereol. 2012; 92(6): 669–74. 

60. Teplitz C, Jones R, McClure M, et al.: Rapid Treponema pallidum clearance from blood and ulcer samples following single dose benzathine penicillin treatment of early syphilis. Venet JM, editor. PLoS Negl Trop Dis 2015; 9(2): e0003492. 

61. Rai AJ, Gelfand CA, Haywood BC, et al.: HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics. 2005; 3(7): 3262–77. 

62. Aguilan-Mahcea A, Kuzyk MA, Domanski D, et al.: The effect of pre-analytical variability on the measurement of MRM-MS-based mid- to high-abundance plasma protein biomarkers and a panel of cytokines. Krauss-Etschmann S, editor. PLoS One. 2012; 7(6):e39293. 

63. Schuchard MD, Meigh RJ, Cocklin SL, et al.: Artifactual isoform profile modification following treatment of human plasma or serum with protease inhibitor, monitored by 2-dimensional electrophoresis and mass spectrometry. Biotechniques. 2005; 39(2): 239–47. 

64. Beskos AG, Teitelbaum SL, et al.: Basic local alignment search tool. J Mol Biol. Wiley-Blackwell; 1995; 215(3): 403–10. 

65. Leverentz SA, Marra CM: Isolation and laboratory maintenance of Treponema
Open Peer Review

Current Peer Review Status: ✔️ ✔️

Version 2

Reviewer Report 19 November 2018

https://doi.org/10.5256/f1000research.18062.r39229

© 2018 Khan M. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mohd M. Khan
University of Maryland, Baltimore, MD, USA

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Mass Spectrometry based Proteomics, Secretomics, and Phosphoproteomics

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 22 August 2018

https://doi.org/10.5256/f1000research.15178.r35202

© 2018 Palzkill T. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Timothy Palzkill
Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, TX, USA

This paper by Van Raemdonck describes the use of mass spectroscopy to identify T. pallidum proteins from plasma and urine from infected patients. If successful, such a method would be very useful in syphilis diagnostics, particularly with regard to reinfection. Thus, the work addresses a significant problem. However, although they could detect isotopically labeled peptides spiked into the samples, they could not detect T. pallidum proteins from the infecting organisms. Limit of
detection experiments suggest this is due to the very low concentrations of T. pallidum proteins in plasma and serum samples. Thus, the main goal produced a negative result. However, there is considerable useful information in this study. The limit of detection experiments with T. pallidum bacteria that have been diluted and were unenriched or enriched with antibody beads provided interesting results on which proteins could be detected and how many bacteria per ml were needed for detection. In addition, the MRM experiments appear to be carefully designed and provide important limit of detection information for future studies. The discussion provides a useful assessment of limiting factors in the direct detection of T. pallidum antigen proteins.

Comments:
1. Some of the description of LOD experiments with dilutions of T. pallidum on page 7, right column, paragraph 2, is difficult to follow. The authors state “In total, eight unique T. pallidum proteins were found in the unenriched and enriched retentate...” but they do not state a dilution. Later in the paragraph, it states “Ten unique T. pallidum proteins were found in the highest concentration...” . This is confusing. What condition does the eight unique proteins refer to?

2. Page 7, right column, paragraph 2. Tp47 is discussed twice in the paragraph with different gene names each time, ie, Tp47 (TP_0547) and Tp47 (TP_0574).

3. Page 3, Introduction, paragraph 1, line 1. “T. pallidum, a non-culturable...” Suggest updating based on recent publication in mBio on culturing T. pallidum.

4. Figure 3. Please indicate the meaning of the asterisks on TP_0249, etc.

Is the work clearly and accurately presented and does it cite the current literature?  
Yes

Is the study design appropriate and is the work technically sound?  
Yes

Are sufficient details of methods and analysis provided to allow replication by others?  
Yes

If applicable, is the statistical analysis and its interpretation appropriate?  
Yes

Are all the source data underlying the results available to ensure full reproducibility?  
Yes

Are the conclusions drawn adequately supported by the results?  
Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
Author Response 03 Oct 2018

Kara Osbak, Institute of Tropical Medicine, Antwerp, Belgium

1. Some of the description of LOD experiments with dilutions of T. pallidum on page 7, right column, paragraph 2, is difficult to follow. The authors state “In total, eight unique T. pallidum proteins were found in the unenriched and enriched retentate...” but they do not state a dilution. Later in the paragraph, it states “Ten unique T. pallidum proteins were found in the highest concentration....”. This is confusing. What condition does the eight unique proteins refer to?

This ambiguous sentence has now been reworded- “In total, eight unique T. pallidum proteins were found in both the unenriched and enriched retentate dilution series in one or more of the concentrations analyzed”. This refers to the proteins that were commonly found in both experiments, regardless of concentration. The details of which are provided in Supplementary Table 3.

The other sentence was also reworded for clarify “Ten unique T. pallidum proteins were found in the highest concentration (10^4 bacteria/ml) four in the enriched retentate sample (N = 10) and non-enriched sample (N = 10), two proteins detected were unique to either the enriched or unenriched samples (Figure 3).”

2. Page 7, right column, paragraph 2. Tp47 is discussed twice in the paragraph with different gene names each time, ie, Tp47 (TP_0547) and Tp47 (TP_0574).

Thanks for pointing this out, this has been rectified to the actual ORF (TP_0574).

3. Page 3, Introduction, paragraph 1, line 1. “T. pallidum, a non-culturable...” Suggest updating based on recent publication in mBio on culturing T. pallidum.

Good idea, this reference has now been added.

4. Figure 3. Please indicate the meaning of the asterisks on TP_0249, etc.

The asterisks refer to “*-proteins selected as candidate biomarkers in this study.”. This information has now been added

Competing Interests: None

Reviewer Report 27 July 2018

https://doi.org/10.5256/f1000research.15178.r35906

© 2018 Khan M. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Mohd M. Khan
University of Maryland, Baltimore, MD, USA

The article “Needle lost in the haystack: multiple reaction monitoring fails to detect *Treponema pallidum* candidate protein biomarkers in plasma and urine samples from individuals with syphilis” focuses on developing targeted proteomics based assay to detect and validate potential biomarkers of *Treponema pallidum* infection. The manuscript is well written, the rationale behind the work is justified, and the methods section is detailed.

I would suggest few points as following:
- Please add the details about participant consent and study approval by the Institutional Review Board (IRB).
- Why only 4 urine samples were analyzed? Which protein marker(s) supposedly should be detected in urine? And which one(s) in plasma? Please consider adding the details and rationale.
- Authors have used microflow for the experiments on quadrupole, which has lower sensitivity. Perhaps targeted experiments using a nanoflow setup, as was done for experiments using orbitrap, will get better sensitivity.
- The synthetic peptides were added after SPE clean-up. Why weren't they added before SPE to determine losses?
- Please supply more information on how LOD was calculated; it was based on the dilution series? The readers can use the explanation of calculations, if provided.
- The spiking experiments should have been done in real matrix?
  - Please comment more on PTP selection? Are they unique? What about labile residues? Was anything done to look at the methionine oxidation? Deamindations? etc.
- The synthetic peptides were 95% pure. Were they quantified? (AAA?)

The paper makes an interesting list of its shortcomings in the discussion, which is helpful. A lot of the critique is already self-proclaimed. The overall conclusion of manuscript is: “A lot of effort and fine-tuning of sample prep/method development will be needed for biomarker discovery and validation.” Biomarker validation is time-consuming and challenging, perhaps some orthogonal experiments should have been done (such as western blotting) to be able to know if the global data acquired using spectral-count was good enough before moving on to the MRM experiments. Nonetheless, authors have done a great job in discussing the shortcomings and in writing the paper.

**Is the work clearly and accurately presented and does it cite the current literature?**
Yes

**Is the study design appropriate and is the work technically sound?**
Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**
Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Mass Spectrometry based Proteomics, Secretomics, and Phosphoproteomics

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

**Author Response 03 Oct 2018**

**Kara Osbak,** Institute of Tropical Medicine, Antwerp, Belgium

Please add the details about participant consent and study approval by the Institutional Review Board (IRB).
The following information is available under the section “Consent and Ethics Approval”: “The prospective observational cohort study (SeTPAT ClinicalTrials.gov # NCT02059525) that provided the clinical samples used in this study was approved by the Institutional Review Board of the Institute of Tropical Medicine Antwerp and the Ethics Committee of the University of Antwerp (13/44/426), Belgium. Written informed consent for publication of the participants’ anonymized details was obtained from the participants.”

Why only 4 urine samples were analyzed? which protein marker(s) supposedly should be detected in urine? and which one(s) in plasma? please consider adding the details and rationale.
As this was an exploratory biomarker study we did not stratify our biomarker selection by biofluid type, thus the potential biomarkers mentioned in this study were theoretically applicable to urine and blood. No previous studies of this type have been performed, hence our selection, as described, was based on our shotgun proteomics studies of *Treponema pallidum* during rabbit infection, literature inferences on previous microarray studies and physiochemical characteristics that would be amendable to MRM detection. Admittedly, only analyzing four urine samples is a small number. It became apparent that our experimental strategy was not working after analyzing the initial set of samples that we decided not to go further. Despite this small number, we believe this information might be useful for other groups considering employing similar methods.

Authors have used microflow for the experiments on quadrupole, which has lower sensitivity. Perhaps targeted experiments using a nanoflow setup, as was done for experiments using orbitrap, will get better sensitivity.
Indeed, one would expect higher sensitivity with the nanoflow set-up, however, to analyze larger volumes of patient material, which might also increase the sensitivity, the microflow
The synthetic peptides were added after SPE clean-up. Why weren't they added before SPE to determine losses?

In this exploratory study, multiple candidate biomarkers were included in the targeted setup to evaluate their potency. Therefore, it was not yet clear in which final concentration these synthetic peptides should be spiked into the samples. At this stage of the study, the synthetic peptides were also not exactly quantified (i.e. AQUA Basic peptides), which would make the determination of losses during sample preparation not precise.

Please supply more information on how LOD was calculated; it was based on the dilution series? The readers can use the explanation of calculations, if provided.

The LOD calculations were based on the dilution series of *T. pallidum* in PBS, which were either enriched or unenriched with magnetic beads coupled with polyclonal antibodies directed against *T. pallidum*. These were then subjected to LTQ Orbitrap analyses. Two unique *T. pallidum* proteins, Cytoplasmic filament protein A (TP_0748) and Lipoprotein antigen Tp47 (TP_0547), were found in the 300 bacteria/ml fraction in the enriched and unenriched samples, respectively. Therefore, the LOD based on a high-resolution LTQ-Orbitrap instrument was approximately 300 bacteria/ml PBS for both the antibody enriched and unenriched samples, meaning there was no significant improvement in LOD using bead enrichment. These results are detailed in Supplementary File 3. Furthermore, rough concentration calculations based on previous studies were presented in Supplementary Table 4 which estimated that the concentration of *T. pallidum* target PTPs in human serum would be in the femtomoles per liter range during human *T. pallidum* infection (calculations presented in Supplementary File 4).

The spiking experiments should have been done in real matrix?

Indeed, the final dilution series of the labeled synthetic peptides, that would be used to determine the absolute concentration of the candidate biomarkers, would have been done in real matrix. However, at this point of the study the goal was to evaluate the abundance of the selected proteotypic peptides before using absolutely quantified labeled peptides (e.g. AQUA Ultimate). Therefore, it was decided to tune and optimize the LC-MS/MS parameters of each labeled peptide without any matrix to determine the most optimal instrument settings.

Please comment more on PTP selection? Are they unique? What about labile residues? Was anything done to look at the methionine oxidation? deamindations? etc

Due to the lack of available MS datasets about the *Treponema pallidum* proteome (no library available), proteotypic peptides of each candidate protein biomarker were predicted in silico. As described, ESP predictor (Fusaro et al, 2009 Nat. Biotechnology) was used to find the most suitable proteotypic peptides based on 550 physico-chemical parameters including potential modifications (e.g. oxidation of methionine, deamidation, phosphorylation etc.). Best scoring peptides were selected for each of the proteins. Moreover, the PTPs that were selected were subjected to BLAST analyses to confirm their uniqueness.
The synthetic peptides were 95% pure. Were they quantified? (AAA?)

During this exploratory study AQUA Basic peptides (Thermo Fisher Scientific) were used to evaluate the abundance of the selected proteotypic peptides. Although the quantity of the PTPs were specified in the leaflet, the peptides were purchased in a lyophilized formulation as one aliquot. Therefore, they are not suited as reference for absolute quantification. In a next step, AQUA Ultimate peptides (with a high concentration precision) would have been used to determine the absolute abundance of the protein biomarkers.

Competing Interests: None